Laverman GD - Search Results

1

Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT).

Beernink JM, Oosterwijk MM, van Boven JFM, Heerspink HJL, Bakker SJL, Navis G, Nijboer RM, Gant CM, Haverkate H, Kruik-Kollöffel WJ, Laverman GD. Beernink JM, et al. Among authors: laverman gd. Front Pharmacol. 2022 Jul 12;13:888110. doi: 10.3389/fphar.2022.888110. eCollection 2022. Front Pharmacol. 2022. PMID: 35903346 Free PMC article.

2

Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria.

Laverman GD, Henning RH, de Jong PE, Navis G, de Zeeuw D. Laverman GD, et al. Am J Kidney Dis. 2001 Dec;38(6):1381-4. doi: 10.1053/ajkd.2001.29262. Am J Kidney Dis. 2001. PMID: 11728979 Clinical Trial.

3

Dual renin-angiotensin system blockade at optimal doses for proteinuria.

Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Laverman GD, et al. Kidney Int. 2002 Sep;62(3):1020-5. doi: 10.1046/j.1523-1755.2002.00536.x. Kidney Int. 2002. PMID: 12164886 Free article. Clinical Trial.

4

Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?

Laverman GD, de Zeeuw D, Navis G. Laverman GD, et al. J Renin Angiotensin Aldosterone Syst. 2002 Dec;3(4):205-13. doi: 10.3317/jraas.2002.042. J Renin Angiotensin Aldosterone Syst. 2002. PMID: 12584664 Free article. Review.

5

Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats.

Bos H, Laverman GD, Henning RH, Tiebosch AT, de Jong PE, de Zeeuw D, Navis G. Bos H, et al. Among authors: laverman gd. J Renin Angiotensin Aldosterone Syst. 2003 Jun;4(2):106-12. doi: 10.3317/jraas.2003.010. J Renin Angiotensin Aldosterone Syst. 2003. PMID: 12806593 Free article.

6

Inter-individual differences in anti-proteinuric response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage.

Kramer AB, Laverman GD, van Goor H, Navis G. Kramer AB, et al. Among authors: laverman gd. J Pathol. 2003 Sep;201(1):160-7. doi: 10.1002/path.1405. J Pathol. 2003. PMID: 12950029

7

Lipid management in the proteinuric patient: do not overlook the importance of proteinuria reduction.

Vogt L, Laverman GD, Dullaart RP, Navis G. Vogt L, et al. Among authors: laverman gd. Nephrol Dial Transplant. 2004 Jan;19(1):5-8. doi: 10.1093/ndt/gfg497. Nephrol Dial Transplant. 2004. PMID: 14671028 Review. No abstract available.

8

Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?

Vogt L, Kocks MJ, Laverman GD, Navis G. Vogt L, et al. Among authors: laverman gd. Minerva Med. 2004 Oct;95(5):395-409. Minerva Med. 2004. PMID: 15467515 Review.

9

Renoprotection with and without blood pressure reduction.

Laverman GD, Andersen S, Rossing P, Navis G, de Zeeuw D, Parving HH. Laverman GD, et al. Kidney Int Suppl. 2005 Apr;(94):S54-9. doi: 10.1111/j.1523-1755.2005.09414.x. Kidney Int Suppl. 2005. PMID: 15752241 Free article. Clinical Trial.

10

Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment.

Vogt L, Laverman GD, van Tol A, Groen AK, Navis G, Dullaart RP. Vogt L, et al. Among authors: laverman gd. Nephrol Dial Transplant. 2006 Jan;21(1):101-6. doi: 10.1093/ndt/gfi068. Epub 2005 Sep 2. Nephrol Dial Transplant. 2006. PMID: 16141462

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters